Blog - Page 223 of 5624 - QualityStocks

ThursdayAug 07, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Advancing Next-Gen Breast Cancer Imaging

Breast cancer continues to be the most commonly diagnosed cancer among U.S. women, excluding nonmelanoma skin cancer Izotropic is preparing to revolutionize breast cancer imaging with its flagship IzoView Breast CT Imaging System In anticipation of future commercialization, Izotropic is initiating a strategic awareness and engagement campaign Accurate detection and diagnosis remain critical challenges in the fight against breast cancer, especially for women with dense breast tissue where mammography falls short. Izotropic (CSE: IZO) (OTCQB: IZOZF) is at the forefront of addressing these gaps through its IzoView Breast CT Imaging System, a contrast-enhanced CT platform designed for enhanced screening precision.…

ThursdayAug 07, 2025 10:10 am

QualityStocksNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Expands Global Patent Protection for AI-Based Explosives Detection

Safe Pro Group (NASDAQ: SPAI), a leader in AI-powered defense solutions, announced the international publication of its patent applications in Australia, Israel, and Europe for its SpotlightAI(TM) explosives detection technology. The Company’s SPOTD system, capable of identifying over 150 explosive threats in drone imagery, is now protected under the Patent Cooperation Treaty in 47 jurisdictions. Backed by a granted U.S. patent valid through 2043, Safe Pro’s proprietary tech supports real-time and cloud-based detection and has identified over 31,600 threats across 7,819 hectares in Ukraine. To view the full press release, visit https://ibn.fm/FLo9j About Safe Pro Group Inc. Safe Pro Group…

ThursdayAug 07, 2025 10:00 am

QualityStocksNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Reports Early Drilling Progress at Swanson Gold Project in Québec

LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) announced the completion of seven diamond drill holes totaling 1,764 meters at its Swanson Gold Project in Québec’s Abitibi Greenstone Belt. Core logging revealed pathfinder minerals, widespread alteration, and a standout 17.9-meter sulphide-rich zone in hole SW-025-038. Samples from three holes have been sent for assay, with results pending. The fully funded 5,000-meter drill program aims to expand known mineralization and test additional regional targets. To view the full press release, visit https://ibn.fm/Ge3Ou About LaFleur Minerals Inc. LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) is focused on the development of…

ThursdayAug 07, 2025 9:59 am

QualityStocksNewsBreaks – Wearable Devices Ltd. (NASDAQ: WLDS, WLDSW) Announces $2.4 Million Warrant Inducement Transaction

Wearable Devices (NASDAQ: WLDS, WLDSW), an award-winning AI-based gesture control technology company, has entered a warrant inducement agreement with an existing institutional investor for the immediate exercise of warrants to purchase up to 1,661,000 ordinary shares at $1.45 per share, generating approximately $2.4 million in gross proceeds. In exchange, the investor will receive 3,322,000 new unregistered warrants in a private placement, exercisable at $1.71 per share upon shareholder approval. Net proceeds will be used for working capital and general corporate purposes. The closing is expected on or about August 7, 2025, subject to customary conditions. To view the full press…

ThursdayAug 07, 2025 9:50 am

QualityStocksNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Launches Multilingual Podcast to Raise Awareness of Breast Imaging Innovation

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging technologies for breast cancer detection, has launched a multilingual podcast series titled Beyond the Mammogram: Rethinking the Future of Breast Imaging. Available in seven languages, the series aims to inform global audiences about limitations in current imaging tools and the need for more accurate technologies like Izotropic’s IzoView Breast CT system. The podcast repurposes public data into educational content for patients, professionals, and stakeholders as the Company moves toward regulatory approval. To view the full press release, visit https://ibn.fm/FDgr9 About Izotropic More information about Izotropic Corporation can…

ThursdayAug 07, 2025 9:45 am

D-Wave Quantum Inc. (NYSE: QBTS): 27% of Surveyed Business Leaders Expect $5M+ ROI from Quantum Optimization Within First Year

Survey by Wakefield Research and D-Wave shows 46% of surveyed business leaders expect $1 million to $5 million ROI from quantum optimization within the first year of adoption. 81% believe they have reached the limits of classical computing’s capabilities for optimization. 53% are planning to integrate quantum computing into their workflows, while 27% are considering it. Quantum optimization is seen as especially valuable in logistics, supply chain, manufacturing, planning and inventory, and R&D. 88% of participants said their organizations would “go above and beyond” for even a 5% improvement in optimization. A new survey released by D-Wave Quantum Inc. (NYSE:…

ThursdayAug 07, 2025 9:00 am

Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule

The trial targets never-smoker non-small cell lung cancer (“NSCLC”) patients, a group with limited treatment options. Japan’s high incidence of never-smoker NSCLC makes it a strategic region for the trial. LP-300 is being tested alongside standard chemotherapy agents in patients who have relapsed after tyrosine kinase inhibitor therapy. Lantern's AI-driven approach may help identify and accelerate development of therapies in underserved cancer markets. Additional trial data from Taiwan and the U.S. is expected later in Q3 2025. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has completed targeted patient…

WednesdayAug 06, 2025 12:45 pm

QualityStocksNewsBreaks – Wearable Devices Ltd. (NASDAQ: WLDS, WLDSW) Launches AI-Powered Touchless Neural Control Project for Military Use

Wearable Devices (NASDAQ: WLDS, WLDSW), a developer of AI-powered touchless sensing wearables, announced the launch of a military-focused project to advance human-machine interface (HMI) technology. The initiative aims to deliver a neural control system enabling soldiers to operate tactical systems through intuitive gestures without physical contact. Powered by the company’s proprietary neural interface and AI-driven sensors, the technology is designed to enhance battlefield efficiency and safety. This move reinforces Wearable Devices’ leadership in neural input innovation and expands its reach into the defense sector. To view the full press release, visit https://ibn.fm/8EJBq About Wearable Devices Ltd. Wearable Devices Ltd. (NASDAQ:…

WednesdayAug 06, 2025 12:10 pm

Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations

Lantern Pharma has introduced an AI-powered module within its RADR(R) platform to assess DDA-DDRi combination therapies. The module uses genomic, transcriptomic, and clinical data, to predict treatment synergy and patient response, and supported the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer. A review of 221 clinical trials informed the development of the predictive algorithm. Non-PARP DDRi combinations with DNA-damaging agents showed strong outcomes in specific cancer subtypes. Lantern is evaluating licensing opportunities to commercialize the module for broader oncology use. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine…

WednesdayAug 06, 2025 12:10 pm

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial

Lantern Pharma (NASDAQ: LTRN) announced that its wholly owned subsidiary, Starlight Therapeutics, has received FDA clearance for an Investigational New Drug (“IND”) application to initiate a Phase Ib/2a clinical trial of STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (“GBM”) at first progression. The study will evaluate safety, tolerability and preliminary efficacy in recurrent GBM, a highly aggressive brain cancer with limited treatment options. STAR-001 is a brain-penetrant DNA-damaging agent designed to exploit DNA repair deficiencies through synthetic lethality, and its effect is enhanced by spironolactone, which induces NER deficiency in tumor cells. The therapy has received…

Site Search

Company Search